BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Novavax

Pfizer

Vaxart

Good news from Merck and Ridgeback caused these stocks to fall.

Why Pfizer, BioNTech, Novavax, and Vaxart Stocks Are Sinking Today

Moderna

The antiviral drug could put a dent into the uptake of COVID-19 vaccines, as countries still struggle to reach herd immunity due to vaccine hesitancy.

Moderna and BioNTech plummet more than 15% following news of Merck's COVID-19 antiviral pill

BioNTech SE (NASDAQ: BNTX) has dosed the first patient with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in Phase 2 clinical trial.  The trial plans to enroll about 200 patients.

BioNTech Starts Dosing In Mid-Stage Colorectal Cancer Immunotherapy Trial

MAINZ, Germany, October 1, 2021 (GLOBE NEWSWIRE) --  BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, today announced that new clinical and preclinical data will be presented in six posters and one presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held both in person and virtually from November 10 - 14, 2021. The presentations will include new data from multiple programs across various drug classes along with first-in-human data for three programs. This is the largest data collection the company will present at a scientific meeting, showcasing BioNTech's diversified oncology pipeline. “The data we will be presenting at SITC 2021 is indicative of our continued pursuit of pathbreaking science and the development of our platform technologies that tailor anti-cancer therapies to individual patient needs,” said Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “We are encouraged by the considerable progress within our oncology portfolio seeing multiple programs now coming to fruition. They represent critical steps for us towards bringing cancer immunotherapy into the next generation and we are looking forward to sharing the data with the scientific community at a key conference.”   Presentation Details:

BioNTech to Present New Clinical and Preclinical Data Across Multiple Immuno-Oncology Programs at 36th SITC Annual Meeting

MAINZ, GERMANY, October 1, 2021 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ: BNTX, “BioNTech” or “the Company”), announced today that the first colorectal cancer patient has been treated with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in a Phase 2 clinical trial. The trial has been initiated in the United States, Germany, Spain and Belgium. It is planned to enroll about 200 patients to evaluate the efficacy of RO7198457 (BNT122) compared to watchful waiting after surgery and chemotherapy, the current standard of care for these high-risk patients. As the second deadliest cancer worldwide, the medical need for novel therapies to treat colorectal cancer remains high.

BioNTech Expands Clinical Oncology Portfolio with First Patient Dosed in Phase 2 Trial of mRNA-based Individualized Immunotherapy BNT122 in Colorectal Cancer Patients

It's not because any of the vaccine makers reported bad news.

Why Moderna, BioNTech, and Novavax Stocks Are Tanking This Week

GlaxoSmithKline

Kadmon Hlds

Novo Nordisk

Sanofi

Sanofi (SNY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that are worth betting on in the current scenario.

3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health

BioNTech has been a phenomenal success story for investors, delivering a ~1,900% gain on investment since its 2019 IPO. Sales of its mRNA vaccine Comirnaty will earn the company in excess of $18bn in 2021, management believes - firmly ahead of expectations.

BioNTech: Stock Price Buoyancy Depends On Comirnaty Sales, But Long Term Value On Pipeline

Dr. Özlem Türeci said she could imagine a scenario in which booster shots were given every 12-18 months, but added that more data were needed.

BioNTech Co-Founder Says Covid Will ‘Become Manageable' and Be Around for Years

The co-founder and chief medical officer of BioNTech, the German firm which developed a Covid-19 vaccine alongside Pfizer, told CNBC that the world "should not live in fear" of the virus.

'Covid will become manageable': BioNTech co-founder says the virus will be with us for years

In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $277.44, marking a +0.33% move from the previous day.

BioNTech SE Sponsored ADR (BNTX) Outpaces Stock Market Gains: What You Should Know

BioNTech, a leader in messenger RNA technology and Pfizer's Covid-19 vaccine partner, has seen its stock decline by almost 9.4% over the last week (five trading days) and by about 17% over the last month. This compares to the S&P 500 which was up about 2% over the last week.

What's New With BioNTech Stock?

Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.

Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Today

Pfizer Inc. PFE, -0.84% and German partner BioNTech SE BNTX, -7.91% said Tuesday they have submitted initial data from the late-stage trial of their COVID-19 vaccine in children aged 5 to 12 to the U.S. Food and Drug Administration, and are seeking an emergency-use authorization to add that patient group to the program. The news comes after the companies released initial data from the trial last week, saying the vaccine had proved safe and effective.

Pfizer and BioNTech seek FDA authorization for vaccination of 5- to 11-year-olds

Pfizer Inc. PFE, -0.84% and German partner BioNTech SE BNTX, -7.91% said Tuesday they have submitted initial data from the late-stage trial of their COVID-19 vaccine in children aged 5 to 12 to the U.S. Food and Drug Administration, and are seeking an Emergency Use Authorization to add that patient group to the program. The news comes after the companies released initial data from the trial last week, saying the vaccine had proved safe and effective.

Pfizer and BioNTech submit initial data to FDA from trial of COVID-19 vaccine in children aged 5 to 12

NEW YORK and MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they have submitted data to the U.S. Food and Drug Administration (FDA) from the Phase 2/3 trial of their COVID-19 vaccine in children 5 to

Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to

IDEXX Laboratories

MercadoLibre

Atlassian

None of it has anything to do with business fundamentals.

Why Are the Nasdaq's Top Growth Stocks Freaking Out Monday?

Shares of COVID-19 vaccine makers, including BioNTech SE - ADR (NASDAQ: BNTX), are trading lower amid continued volatility in the space as investors weigh booster shot progress. Pfizer CEO Albert Bourla recently predicted a return to 'normal life' within a year with a likely need for annual shots.

Why BioNTech Shares Are Falling

Volatility remains high among vaccine stocks as two CEOs predict the end of the pandemic next year.

Why BioNTech, Moderna, and Novavax Stocks Are Sliding Today

The decision is in line with FDA authorization for booster shots of the Pfizer-BioNTech vaccine.

CDC director endorses Pfizer booster for frontline workers, overruling advisory panel

The Centers for Disease Control and Prevention (CDC) backed a booster shot of Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) COVID-19 vaccine for Americans aged 65 and older and adults with an underlying medical condition. It also said that residents of nursing homes and other long-term-care facilities should also get the extra shots.

Pfizer/BioNTech COVID-19 Boosters For Seniors, Certain Vulnerable Adults Coming Soon - CDC Panel Recommends

Dr. Rochelle Walensky recommended workers in high-risk settings to also be offered Pfizer Covid booster doses, despite the CDC advisers voting against this group getting the third shot.

CDC Director Backs Pfizer Booster Shots For Seniors, Vulnerable—And High-Risk Workers

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging update in coronavirus vaccine.

Will Pfizer ETFs Soar on FDA's COVID-19 Vaccine Booster Approval?

An advisory committee to the agency rejected a recommendation for boosters for people aged 18 to 64 in an occupational or institutional setting where the risk of transmission is high.

CDC Advisors Recommend Pfizer Booster Shots for Older Americans

A panel advising the CDC poured over new data on vaccines this week before recommending boosters for adults aged 65+, but against shots for workers.

News for BioNTech SE Stock (BNTX)